for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Ngm Bio Begins Early-Stage Study Of Ngm120 For Cancer And Cancer Anorexia/Cachexia Syndrome

Feb 11 (Reuters) - NGM Biopharmaceuticals Inc:

* NGM BIO ANNOUNCES INITIATION OF PHASE 1A/1B CLINICAL STUDY OF NGM120 FOR THE POTENTIAL TREATMENT OF CANCER AND CANCER ANOREXIA/CACHEXIA SYNDROME (CACS) Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up